home / stock / ogn / ogn news


OGN News and Press, Organon & Co. From 05/05/22

Stock Information

Company Name: Organon & Co.
Stock Symbol: OGN
Market: NYSE
Website: organon.com

Menu

OGN OGN Quote OGN Short OGN News OGN Articles OGN Message Board
Get OGN Alerts

News, Short Squeeze, Breakout and More Instantly...

OGN - Organon posts Q1 beat as topline growth returns thanks to established brands

Organon (NYSE:OGN), the Merck (MRK) spinoff focused on women’s health and biosimilars, is trading ~4% higher in the pre-market Thursday after reporting better than expected financials for Q1 2022 thanks to the outperformance of its established brands segment. After back-...

OGN - Organon Non-GAAP EPS of $1.65 beats by $0.35, revenue of $1.57B beats by $50M

Organon press release (NYSE:OGN): Q1 Non-GAAP EPS of $1.65 beats by $0.35. Revenue of $1.57B (+4.0% Y/Y) beats by $50M. Board of Directors declares quarterly dividend of $0.28 per share Full year 2022 financial guidance ranges affirmed Revenue of $6.1B-$6.4B vs. $6.26B consensus. For furthe...

OGN - Organon Reports Results for the First Quarter Ended March 31, 2022

First quarter 2022 revenue of $1,567 million Net income from continuing operations of $348 million, or $1.36 per diluted share; Adjusted net income from continuing operations of $420 million, or $1.65 per diluted share Adjusted EBITDA of $647 million Board of Directors dec...

OGN - Organon Q1 2022 Earnings Preview

Organon (NYSE:OGN) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $1.30 and the consensus Revenue Estimate is $1.52B (+0.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue es...

OGN - Goldman highlights top sector picks for high dividend growth and yield

Goldman Sachs boosted its forecast for dividend growth this year, with earnings growth the primary driver. The equity team now sees dividend growth of +10% for 2022. S&P 500 (SP500) (SPY) dividends per shares "grew by +11% year/year in 1Q 2022," strategist David Kostin wrote in a note. "I...

OGN - Tracking Kahn Brothers Portfolio - Q1 2022 Update

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...

OGN - Organon: Maximum Optimism

Biosimilar sales were $118 million in Q4 2021, up 14.6% from Q4 2020. Organon's dividend yield is around 3.5%, which is one of the largest in the pharmaceutical industry. In July 2023, the company expects to start selling the biosimilar Humira, whose patented drug brought AbbVie a...

OGN - Organon wins Buy rating at Goldman Sachs on undervalued Women's Health unit

Goldman Sachs has launched its coverage on Organon (NYSE:OGN), arguing, among other things, that the market hasn’t adequately appreciated the Women's Health (WH) business of the Merck (MRK) spinoff. The price target set to $40 per share implies a premium of ~26% to the last close. The ...

OGN - EMA panel recommends extending indication for Organon's fertility treatment Elonva

The European Union drug regulator's Committee for Medicinal Products for Human Use recommended extending the indication for Organon's (NYSE:OGN) fertility treatment, Elonva.  The drug regulator said Elonva is indicated for the treatment of adolescent males, that are 14 years and older, w...

OGN - Organon To Report First Quarter Results and Host Conference Call on May 5, 2022

Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon website at https://www.organon.c...

Previous 10 Next 10